By making tumor cells more susceptible to oxidative stress, NRF2 inhibitors, like Brusatol [210,211,212] and ML385 [213,214], have been studied for their capacity to prevent NRF2 activation and improve the efficacy of chemotherapy and radiation therapy [215,216]. This evidence concerns the gene NFE2L2 and neoplasm.